Your browser doesn't support javascript.
loading
Chronic Myelomonocytic Leukemia-Associated Immune Thrombocytopenic Purpura: A Report of a Rare Case and a Review of Literature.
Nasreddine, Ghadir M; Farhat, Solay; Hammoud, Zeinab M; Saad, Firas; Saad, Wajih.
Afiliação
  • Nasreddine GM; Department of Hematology and Oncology, Lebanese University, Faculty of Medical Sciences, Beirut, LBN.
  • Farhat S; Department of Hematology and Oncology, Lebanese University, Faculty of Medical Sciences, Beirut, LBN.
  • Hammoud ZM; Department of Hematology and Oncology, Lebanese University, Faculty of Medical Sciences, Beirut, LBN.
  • Saad F; Department of Hematology and Oncology, Morristown Medical Center, New Jersey, USA.
  • Saad W; Department of Hematology and Oncology, Al-Zahraa Hospital University Medical Center, Beirut, LBN.
Cureus ; 16(3): e55904, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38595873
ABSTRACT
Chronic myelomonocytic leukemia (CMML) presents as a complex hematologic malignancy with myelodysplastic and myeloproliferative features. Our case report explores the rare coexistence of CMML with immune thrombocytopenic purpura (ITP) in a 63-year-old female patient. CMML diagnosis followed World Health Organization criteria, and the patient was classified as having high-risk myelodysplastic syndrome (MDS)-CMML stage 2. Initial treatment with subcutaneous azacytidine for CMML proved partially effective, highlighting persistent severe thrombocytopenia. Subsequent investigations revealed secondary ITP associated with Crohn's disease. Conventional ITP therapies, including high-dose steroids and intravenous immunoglobulin, showed limited efficacy. Eltrombopag, a thrombopoietin receptor agonist, was initiated, resulting in the normalization of platelet counts within six weeks. Our case emphasizes the diagnostic challenges and intricate treatment landscape of CMML-associated ITP, suggesting eltrombopag as a potential therapeutic option in refractory cases. The study contributes to the evolving understanding of the complex interplay between myeloid disorders and immune-mediated hematological conditions, calling for personalized and multidisciplinary approaches to enhance patient outcomes.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article